Integrins are essential in the complex multistep process of angiogenesis and are thus attractive targets for the development of antiangiogenic therapies. Integrins are antagonized by disintegrins and C-type lectin-like proteins, two protein families from snake venom. Here, we report that CC-PLA2-1 and CC-PLA2-2, two novel secreted phospholipases A 2 (PLA 2 ) isolated from Cerastes cerastes venom, also showed anti-integrin activity. Indeed, both PLA 2 s efficiently inhibited human brain microvascular endothelial cell adhesion and migration to fibrinogen and fibronectin in a dose-dependent manner. Interestingly, we show that this anti-adhesive effect was mediated by a5b1 and av-containing integrins. CC-PLA2s also impaired in vitro human brain microvascular endothelial cell tubulogenesis on Matrigel and showed antiangiogenic activity in vivo in chicken chorioallantoic membrane assay. The complete PLA 2 cDNAs were cloned from a venom gland cDNA library. Mature CC-PLA2-1 and CC-PLA2-2 contain 121 and 120 amino acids, respectively, including 14 cysteines each and showed 83% identity. Tertiary model structures of CC-PLA2-1 and CC-PLA2-2 were generated by homology modeling. This is thus the first study describing an antiangiogenic effect for snake venom PLA 2 s and reporting first clues to their mechanism of action on endothelial cells.
Angiogenesis is fundamental to normal healing, reproduction and embryonic development. However, this process is also important in the pathogenesis of a broad range of disorders such as arthritis and cancer. 1 Angiogenesis is thus required to sustain malignant cells with nutrients and oxygen for tumors to grow beyond a microscopic size. The development of new blood vessels in the tumor also facilitates metastasis formation by providing a mechanism to increase the likelihood of tumor cells entering the blood circulation. Thus, the microvascular endothelial cell recruited by a tumor is an important target in cancer therapy and has the advantage of being genetically stable. Therefore, treating both the cancer cell and the endothelial cell in a tumor may be more effective than treating the cancer cell alone. 2 Angiogenesis is a complex process, typically consisting of enzymatic degradation of the basement membrane, vascular endothelial cell migration into perivascular space, proliferation and alignment to form capillary-like structures, and new vessel formation. All these events are supported by the action of the integrin adhesion receptors. 3 Integrins are heterodimeric, transmembrane glycoproteins that are involved in cell-extracellular matrix (ECM) and sometimes in cell-cell adhesion. Integrins are composed of noncovalently associated a-and b-subunits that can assemble into at least 24 known distinct integrins, and heterodimer composition generally confers ligand specificity. 4 In addition to their structural role as bridges between the ECM proteins and the actin cytoskeleton, integrins also have a critical role in signal transduction events that regulate cell shape, survival, proliferation and migration. 5 Snake venom contains components able to disrupt cell-ECM interactions. Among these molecules, disintegrins are the most widely characterized and they are now studied for potential use in medicine (for a review, see McLane et al 6 ).
Most disintegrins contain an Arg-Gly-Asp (RGD) or RGDlike sequence in the C-terminal half of the molecule, which is essential to their ability to block integrin interaction with ligands. 7 Another family of venom peptides, the C-type lectin proteins (CLPs), 8 has also been reported to impair cell-ECM interactions. They inhibit cell adhesion, migration, proliferation and angiogenesis by interacting with integrins. [9] [10] [11] [12] Phospholipases A2 (PLA 2 , EC 3.1.1.4) are generally Ca 2 þ -dependent enzymes that catalyze the hydrolysis of the sn-2 fatty acyl bond of glycerophospholipids. Secreted PLA 2 s are small proteins (14-18 kDa) usually containing 5-8 disulfide bonds and possessing a His/Asp dyad required for catalysis. 13 Snake venoms contain high amounts of secreted PLA 2 s that belong to either group I (elapid and hydrophid venoms) or group II (viperid and crotalid venoms). In addition to their possible role in the digestion of preys, snake venom PLA 2 s exhibit a wide spectrum of pharmacological effects by interfering in normal physiological processes. They include neurotoxicity, myotoxicity, hemolytic activity, anticoagulant and antiplatelet effects (see Kini 14 for a review). Furthermore, they can show antiviral and bactericidal properties. [15] [16] [17] Several lines of evidence indicate that, in many instances, these effects are independent of the catalytic phospholipid hydrolysis. Moreover, to explain the susceptibility of a tissue to a particular PLA 2 , it has been proposed that venom PLA 2 s have selective membrane-binding sites that direct them to specific cellular targets, and that such binding is crucial in their mechanism of action. 14 In this work we reported in vitro and in vivo antiangiogenic activities of two secreted PLA 2 s (CC-PLA2-1 and CC-PLA2-2) isolated from Cerastes cerastes venom, the Tunisian horned viper. We showed that their effect is likely due to the inhibition of a5b1 and av-containing integrins.
MATERIALS AND METHODS Reagents
Venom was collected from C. cerastes snake in the Pasteur Institute's serpentarium (Tunis, Tunisia) and stored at À201C. Dulbecco's modified Eagle's medium (DMEM) and RPMI 1640 medium were purchased from Lonza (LevalloisPerret, France), fetal calf serum (FCS) and horse serum were from Invitrogen (Cergy-Pontoise, France), and endothelial cell growth supplement (ECGS) was from BD Biosciences (Le Pont de Claix, France). Poly-L-lysine, human fibrinogen and mouse laminin-1 were from Sigma (St Quentin Fallavier, France). Rat type I collagen was from Upstate (Lake Placid, NY, USA) and human fibronectin from Millipore (St Quentin en Yvelines, France). Human vitronectin was purified according to Yatogho et al. 18 Rat monoclonal antibody (mAb) 69.6.5 against av integrin was produced as previously described. 19 Mouse mAbs FB12 (anti-a1), P1B5 (anti-a3), P1D6 (anti-a5), LM609 (anti-avb3) and P1F6 (anti-avb5) were purchased from Millipore. Mouse mAbs Gi9 (anti-a2b1), Lia1/2 (anti-b1) and rat mAb GoH3 (anti-a6) were from Beckman Coulter (Marseille, France).
Cell Culture
Human colonic adenocarcinoma (HT29-D4) 20 and fibrosarcoma (HT1080) (ATCC) cells were routinely cultured in DMEM containing 10% FCS. Human leukemia (K562; ATCC) and ovarian adenocarcinoma (IGROV1) cells, provided by Dr J Benard (Institut Gustave Roussy, Villejuif, France) were cultured in RPMI 1640 medium containing 10% FCS. Rat pheochromocytoma (PC12; ATCC) cells were cultured in DMEM supplemented with 5% FCS and 10% heat-inactivated horse serum. Immortalized human brain microvascular endothelial cells (HBMECs), kindly provided by Dr K Kim (JHU, Baltimore, MA, USA), were maintained in RPMI 1640, 20% heat-inactivated FCS, ECGS (50 mg/ml), heparin (50 U/ml) and L-glutamine (2 mM).
Cell Adhesion and Migration Assays
Adhesion assays were performed as previously described. 21 Briefly, cells in single-cell suspension were added to wells coated with purified ECM proteins and allowed to adhere to the substrata for 1 h (HBMEC, HT1080, IGROV1 and PC12 cells) or 2 h (HT29-D4 and K562 cells) at 371C. Incubation of K562 cells was performed in the presence of 1 mM MnCl 2 and 100 nM phorbol 12-myristate 13-acetate (PMA) to activate a5b1 integrin. After washing, attached cells were fixed, stained by 0.1% crystal violet and lysed with 1% SDS. Absorbance was then measured at 600 nm.
In vitro cell migration was evaluated using haptotaxis assays in modified Boyden chambers (NeuroProbe Inc., Bethesda, MD, USA) as previously described 21 in the presence of DMEM/10% FCS. After staining cells with 0.1% crystal violet, cell migration was quantified by measure of absorbance at 600 nm.
Solid-Phase Receptor Assay
Microtiter plates (96-well) were precoated with 0.5 mg CC-PLA2 for 2 h at 371C, then blocked with PBS/3% BSA, overnight at 41C. HBMECs were solubilized with 20 mM Tris-HCl (pH 7.6), 200 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% BSA and a mixture of protease inhibitors (1 mM PMSF, 500 U/ml aprotinin, 1 mg/ml leupeptin, 1 mM pepstatin, 1 mM iodoacetamide and 1 mM o-phenanthroline) for 30 min at 41C. The extract was clarified by centrifugation at 10 000 g for 10 min at 41C and then added (200 mg of total proteins) to CC-PLA2-coated wells for 4 h at 41C. Unbound proteins were removed by three washes with PBS/0.1% Triton X-100. Integrins binding was detected by sequential incubations with 100 ml of 10 mg/ml mouse mAbs AMF-7 (anti-av), Sam-1 (anti-a5b1) or Gi9 (anti-a2b1) and with sheep antimouse IgG HRP-conjugated antibodies for 1 h at room temperature. Finally, 100 ml of peroxidase substrate (3, 3 0 ,5,5 0 -tetramethylbenzidine) were added for 10 min at room temperature, the reaction was stopped by adding 50 ml of 1 mol/l H 2 SO 4 and absorbance was measured at 450 nm.
Chemical Inhibition of PLA 2 Activity Chemical modification of CC-PLA2-1 and CC-PLA2-2 enzymes by p-bromophenacyl bromide (BPB) and enzymatic activity measurements were performed as described. 22 Tubulogenesis on Matrigelt and Chicken Chorioallantoic Membrane Assay Tubulogenesis assays were performed using HBMEC cells on Matrigel-coated wells as already described. 11 The capillarylike structures formed in the gel were quantified using ImageJ software.
Chick embryos from 3-day-old eggs were opened and placed in double Petri dishes with water for humidity. After 5 days at 371C, filter paper disks (diameter 6 mm) soaked in buffer (0.9% NaCl) or CC-PLA2-1 or CC-PLA2-2 (0.5 or 1 mM) were applied on the chicken chorioallantoic membrane (CAM). After 48 h, spontaneous angiogenesis was observed and photographed with a digital camera at Â 10 magnification.
To check the effect of CC-PLA2-1 and CC-PLA2-2 on growth factor-induced angiogenesis, bFGF or vascular endothelial growth factor (VEGF) (200 ng per embryo)-impregnated filter disks were administered topically on the CAM of 8-day-old embryos. After 24 h, CC-PLA2-1 and CC-PLA2-2 (1 mM) were applied to the CAM and blood vessels were photographed after 72 h of incubation.
cDNA Library Construction and Clones Screening
The first strand of cDNA was reverse-transcribed by a standard method according to the manufacturer's instructions (Promega) using the universal oligo(dT)-containing adapter primer 5 0 -CCAGTGAGCAGAGTGACGAGGACTCGAGCTC AAGCTT 16 -3 0 (Proligo). 12 ml of 0.1% diethylpyrocarbonatetreated water containing 0.1 mg of primer and 1 mg of total venom gland RNA were heated to 701C for 10 min to denature any possible secondary structure, cooled in ice and mixed with 4 ml of 5 Â First Strand Buffer, 2 ml of 0.1 M dithiothreitol, 1 ml of RNAsin (ribonuclease inhibitor at 40 U/ ml), 1 ml of dNTP (10 mM each) and 200 U RNase H-free Moloney murine leukemia virus reverse transcriptase. The reaction mixture was incubated at 421C for 1 h, followed by 10 min at 951C to inactivate the enzyme.
CC-PLA2 encoding sequences were amplified by PCR using venom gland cDNAs as template and the following primers: 5 0 -TCTGGATTCGGGAGGATGAGG-3 0 (forward primer, corresponding to highly conserved 5 0 untranslated region of reported cDNA sequences encoding group II PLA 2 s) and 5 0 -GAGGACTCGAGCTCAAGC-3 0 (reverse primer, which is contained in the oligo(dT) primer). The PCR protocol included an initial denaturation step at 951C for 5 min followed by 35 cycles of denaturation (1 min at 951C), annealing (1 min at 551C) and extension (1 min at 721C), and a final extension step of 7 min at 721C. The amplified fragments were separated on 1% agarose gel electrophoresis, purified using QIAquick gel extraction kit (Qiagen) and cloned into pGEM-T vector (Promega) before transforming Escherichia coli MOSBlue cells.
Positive clones, selected by growing the transformed cells in Luria Broth medium containing 10 mg/ml ampicillin, were confirmed by PCR amplification using the above primers and sequencing of the inserts on an Applied Biosystems model 377 DNA sequencer.
Molecular Modeling
Tertiary model structures of CC-PLA2-1 and CC-PLA2-2 were generated by homology modeling with the program Modeller 9v2. 23 Homologous polypeptides with known structures were identified by a Blast2 search of the PDB database (RCSB organization) using the sequence of CC-PLA2-1 and CC-PLA2-2 as entry. The solution structures of phospholipase A 2 inhibitor from Vipoxin (PDB code 1VPI) and Rv4/Rv7 complexes (PDB code 1OQ5) were used as templates. A total of 20 models were generated for each protein.
All their pdb files were analyzed for their energetic and geometric characteristics. For each protein, only one model combining the best Ramachandran plot (http://swift.cmbi. ru.nl/servers/html//ramaplot.html), and good scores for the objective function values, 23 and the VICTOR/FRST energy function proposed by Tosatto 24 (http://protein.cribi.unipd.it/ frst/) was considered. The best models were then visualized with the ViewerLite50 program (http://www.accelrys.com/ products/dstudio/).
RESULTS

Molecular Cloning of CC-PLA2-1 and CC-PLA2-2 and Sequences Analysis
We recently purified to homogeneity and partially sequenced two nontoxic PLA 2 s with a relatively high enzymatic activity from C. cerastes snake venom. These enzymes, named CC-PLA2-1 and CC-PLA2-2, inhibited blood coagulation, platelet aggregation, and tumor cell adhesion and migration. 22 In this study, we cloned the cDNAs encoding PLA 2 isoforms from a C. cerastes venom gland cDNA library, amplified by PCR and sequenced.
Among the clones obtained, we retained two cDNAs that showed a complete identity with the N-terminal amino-acid sequences of purified CC-PLA 2 s as determined by Edman degradation (Figure 1a, underlined) . Both nucleotide sequences were deposited in GenBank under the accession numbers FJ754186 (CC-PLA2-1) and FJ754187 (CC-PLA2-2). The cDNAs contain open reading frames of 411 and 408 bp that encode two polypeptides of 137 and 136 aminoacid residues, respectively, including a 16 amino-acid signal peptide (Figure 1a) . Mature CC-PLA2-1 and CC-PLA2-2 thus contain, respectively, 121 and 120 amino acids, including 14 cysteines each. The peptide sequences of CC-PLA2-1 and CC-PLA2-2 are very similar (83% identity). Indeed, they only show 18 amino acids and 1 deletion at position 91 in CC-PLA2-2 sequence. The calculated molecular mass of CC-PLA2-1 and CC-PLA2-2 is 13521.51 and 13259.42 Da, respectively. These values are slightly lower than those determined by mass spectrometry (13737.52 and 13705.63 Da, respectively), likely due to the presence of saccharide residues. 22 The theoretical isoelectric points, estimated by the Expasy tools (http://expasy.org/tools/pi_tool.html), were of 4.92 and 4.86 for CC-PLA2-1 and CC-PLA2-2, respectively. Blast search and amino-acid sequence alignment show that the two CC-PLA 2 s have a high sequence identity with group IIA snake venom PLA 2 s (Figure 1b) . The highest amino-acid identity with CC-PLA2-1 was observed with EC1 PLA2 from Echis coloratus snake venom (75%), ammodytin I2 (D) Integrins, new targets for PLA 2 R Kessentini-Zouari et al isoform from Vipera ursinii (75%), PLA2-CERCE from Pakistani C. cerastes (64%) and RV7 from Daboia russelii siamensis (62%). CC-PLA2-1 sequence also showed 45% identity with KDR-bp, a KDR binding PLA 2 from Agkistrodon piscivorus (Figure 1b) .
CC-PLA2-1 and CC-PLA2-2 Affect Adhesion and Migration of Endothelial Cells
Although it has been reported that snake venom PLA 2 s exert a cytotoxic activity on tumor cells, 17, 25 we showed that the two CC-PLA2s are not cytotoxic on human fibrosarcoma (HT1080) and melanoma (IGR39) cell lines. 22 In this study, we used HBMECs to check the effect of CC-PLA2s on angiogenesis. We observed that none of the CC-PLA2s, at 1 mM, neither induced cell death (data not shown), nor inhibited cell growth after 4 days in culture (Figure 2a) . However, both CC-PLA2s affected cell adhesion depending on the purified ECM protein used as substratum (Figure 2b ). Both CC-PLA2-1 and CC-PLA2-2 at 1 mM abolished the attachment of HBMEC to fibrinogen and dramatically reduced their adhesion to fibronectin, whereas no effect was observed on type I collagen, vitronectin or laminin 1. The inhibition likely involved the integrin family of adhesion receptors, as adhesion of HBMEC was not affected when using the integrinindependent substratum poly-L-lysine. Both CC-PLA2-1 and CC-PLA2-2 inhibited cell attachment in a dose-dependent manner (Figure 2c ). The IC 50 values were, respectively, 0.12 and 0.20 mM for fibrinogen and 0.12 and 0.30 mM for fibronectin.
Moreover, as already observed with tumor cells, 22 alkylated CC-PLA2s were still able to inhibit HBMEC adhesion as efficiently as the active enzymes, indicating a clear dissociation of the anti-adhesive effect of CC-PLA2s and their catalytic activity (Figure 2d) .
Cell migration can be considered as a finely regulated process including successive steps of cell adhesion and de-adhesion. Because CC-PLA2s block HBMEC cell adhesion, we also looked at their effect on cell migration using haptotaxis assays in modified Boyden chambers. As illustrated in Figure 3a , both CC-PLA2s at 1 mM completely blocked HBMEC cell migration toward fibronectin. The inhibitory effect of CC-PLA2s on cell migration to fibronectin and to fibrinogen was dose dependent, with an inhibition of 50-65% at a concentration as low as 0.1 mM (Figure 3b ).
CC-PLA2-1 and CC-PLA2-2 Effects are Mediated by a5b1 and av Integrins Because HBMEC adhere on fibrinogen and fibronectin through a5b1 and av-containing integrins (see Supplementary Figure S1 ), these integrins are good candidate targets for Figure 2 CC-PLA2-1 and CC-PLA2-2 inhibit endothelial cells adhesion. (a) HBMEC were seeded at 5000 cells per well and allowed to spread for 2 h at 371C. They were then cultured without ( ) or with 1 mM of CC-PLA2-1 ( ) or CC-PLA2-2 ( ) for the indicated time. At daily intervals, cells were fixed with 1% glutaraldehyde, stained with 0.1% crystal violet, solubilized by SDS and absorbance was measured at 600 nm. (b) HBMEC were preincubated without ( ) or with 0.5 mM of CC-PLA2-1 ( ) or CC-PLA2-2 ( ) for 30 min at room temperature. Cells were then added to 96-well microtiter plates coated with 10 mg/ml type I collagen (Coll I), fibronectin (Fn), vitronectin (Vn) or laminin-1 (Ln 1), or with 50 mg/ml fibrinogen (Fg) or poly-L-lysine (PLL) and allowed to adhere for 1 h at 371C. After washing, adherent cells were fixed, stained with crystal violet, solubilized by SDS and absorbance was measured at 600 nm. (c) HBMECs were preincubated with the indicated concentrations of CC-PLA2-1 ( ) or CC-PLA2-2 ( ) and allowed to adhere to plates coated with fibrinogen or fibronectin as described above. (d) HBMECs were preincubated without (control) or with 1 mM of purified CC-PLA2-1 or CC-PLA2-2 (native) or with enzymes previously chemically treated in the absence (ÀBPB) or in the presence ( þ BPB) of p-bromophenacyl bromide. Cells were then allowed to adhere to plates coated with fibrinogen as described above. All data shown are means ( ± s.d.) from at least three experiments performed in triplicate.
Integrins, new targets for PLA 2 R Kessentini-Zouari et al the inhibitory effects of CC-PLA2s. To test this supposition, we conducted several assays. We first performed adhesion assays to immobilized CC-PLA2s in the presence of blocking antibodies directed against various integrin subunits. As illustrated in Figure 4a , both CC-PLA2s were efficient in allowing HBMEC attachment. Antibodies against av integrin subunit completely abolished cell adhesion to CC-PLA2s, whereas antibodies against avb3 reduced cell attachment by about 75-80%, suggesting that av integrins may be involved.
We next checked the anti-adhesive effect of CC-PLA2s on various cell/ECM protein pairs involving each one a sole integrin: a1b1 (PC12/type IV collagen), a2b1 (HT1080/type I collagen), a5b1 (K562/fibronectin), a6b4 (HT29-D4/laminin-1), avb3 (IGROV1/fibrinogen), avb5 (HT29-D4/vitronectin) and avb6 (HT29-D4/fibronectin). As shown in Figure 4b , none of the CC-PLA2s modified cell adhesion through a1b1, a2b1, a6b4 or avb5 integrins. However, both PLA 2 s efficiently blocked the adhesive function of a5b1, avb3 and avb6 integrins.
The integrin adhesive function can be regulated by subcellular relocalization or by intracellular signals, a phenomenon known as inside-out signaling. We therefore used a solid-phase binding assay to test the interaction of the integrins with immobilized CC-PLA2 in a cell-free environment. In these conditions, we observed that solubilized av and a5b1 integrins still bound to both CC-PLA2s, whereas binding of a2b1 integrin was very low (Figure 4c ). Altogether these results suggest that CC-PLA2s likely inhibit cell adhesion and migration by interacting directly with av and a5b1 integrins.
CC-PLA2-1 and CC-PLA2-2 Display in vitro and in vivo
Antiangiogenic Activity Cell adhesion and migration are integral parts of the angiogenic process and affect tubulogenesis. Because HBMEC tubulogenesis can be inhibited by specific anti-av antibodies and by C-type lectins that target av-containing integrins, 11 we hypothesized that PLA 2 -mediated impairment of HBMEC adhesion and migration could therefore affect tubulogenesis. HBMECs were thus treated with 1 mM of CC-PLA2 and in vitro tubulogenesis assays were performed on Matrigel. As shown in Figure 5A , both CC-PLA2s completely blocked in vitro tubulogenesis. Besides, this effect was dose dependent ( Figure 5B ).
To further characterize the antiangiogenic properties of CC-PLA2s, we used the in vivo CAM assay. Both CC-PLA2-1 and CC-PLA2-2 (1 mM) strongly reduced vasculature development. A marked reduction in the number of new capillaries and branching, without affecting the mature blood vessels, was also observed ( Figure 5C, b and c) . Quantification shows that the total vessel length was reduced by 76 and 78% for CC-PLA2-1 and CC-PLA2-2, respectively, compared with the untreated conditions ( Figure 5D ). Chicken CAM assays were also performed under the induction of angiogenesis by bFGF or VEGF (200 ng per embryo) with or without the addition of CC-PLA2. Either bFGF or VEGF induced a pronounced angiogenic response in this model ( Figure 5C, d and g, respectively) . Both CC-PLA2-1 and CC-PLA2-2 reduced by 54% the bFGF-induced angiogenesis ( Figure 5C , e and f; Figure 5D ). CC-PLA2-1 and CC-PLA2-2 also reduced by 60 and 66%, respectively, VEGF-induced angiogenesis ( Figure 5C , h and j; Figure 5D ). Consequently, we can conclude that both CC-PLA2s are able to block normal as well as induced angiogenesis in vitro and in vivo.
Molecular Modeling of CC-PLA2-1 and CC-PLA2-2
The three-dimensional models of CC-PLA2-1 and CC-PLA2-2, obtained using solution structures of PLA 2 inhibitor from Vipoxin (PDB code 1VPI) 26 and Rv4/Rv7 complex (PDB code 1OQ5) 27 as templates, were refined with suitable stereochemical parameters. Statistics for the Ramachandran plot from an analysis gave 94.2% for CC-PLA2-1 and 96.6% for CC-PLA2-2 of nonglycine residues in the most favored regions. The overall structures of CC-PLA2-1 and CC-PLA2-2 resemble that of classic group II PLA 2 enzymes (Figure 6) bridges are identical to that of classic group II PLA 2 
DISCUSSION
PLA 2 s are among the best-characterized components of snake venom. In addition to their possible role in the digestion of the prey, many snake venom PLA 2 s are toxic and exhibit a large variety of pharmacological effects, including tissues toxicity, modulation of platelet aggregation and hypotension. 14 In this work, we demonstrated for the first time that CC-PLA2-1 and CC-PLA2-2, two snake venom PLA 2 enzymes from C. cerastes venom, can also exert antiangiogenic activity in vitro and in vivo. In some cases, in vivo tissue damages caused by PLA 2 s have been correlated with in vitro cytotoxicity. 28, 29 However, the antiangiogenic activity of CCPLA2s is likely not due to any cytotoxic effect on HBMEC cells. Indeed, endothelial cells proliferation was not affected by CC-PLA2s over a 4-day period (see Figure 2a) , cells did not detach from the substratum during the test and no cell debris could be observed. Moreover, their proliferative potential was neither altered by treating cells in suspension, as performed in most of the experiments, excluding the possibility that endothelial cells undergo apoptosis secondary to anoikis (data not shown). Rather, the CC-PLA2s, used at concentrations lower than 1 mM, efficiently inhibit several key steps of the angiogenic process in vitro, such as endothelial cell adhesion, migration and tubulogenesis.
To the best of our knowledge, such inhibitory activities of secreted PLA 2 on endothelial cells have not been reported to date. Some studies have suggested instead an increased motility of epithelial cells and an increased invasion of fibroblasts in response to Naja naja PLA 2 . 30, 31 In the case of endothelial cells, Rizzo et al 32 also showed evidences for a chemotactic effect of secreted PLA 2 . This discrepancy with our own observations may be due to the differences in the techniques, as we used haptotaxis assays to analyze cell migration. Moreover, we analyzed the effect of CC-PLA2s on Figure 4 Anti-a5 and anti-av antibodies inhibit cell adhesion to CC-PLA2s. (a) HBMECs were preincubated without (À) or with function-blocking antibodies against integrin subunits for 30 min at room temperature. Antibodies were used as follow: FB12 (anti-a1), Gi9 (anti-a2b1), GoH3 (anti-a6), 69.6.5 (anti-av), Lia1/2 (anti-b1) and LM609 (anti-avb3) at 10 mg/ml and P1F6 (anti-avb5) at 1:100. Cells were then added to 96-well microtiter plates coated with 1 mM CC-PLA2-1 or CC-PLA2-2 for 1 h at 371C. After washing, adherent cells were stained with crystal violet, solubilized by SDS and absorbance was measured at 600 nm. Cell adhesion to type I collagen (Coll I) is shown as a control. Data are means ( ± s.d.) from 3-5 experiments performed in triplicate. (b) Adhesion assays were performed with various cell/ECM protein pairs involving each one a sole integrin: a1b1 (PC12/type IV collagen), a2b1 (HT1080/type I collagen), a5b1 (K562/fibronectin), a6b4 (HT29D4/laminin-1), avb3 (IGROV1/fibrinogen), avb5 (HT29D4/vitronectin) and avb6 (HT29D4/fibronectin). Cells were preincubated in the absence ( ) or in the presence of 1 mM CC-PLA2-1 ( ) or CC-PLA2-2 ( ) and plated on ECM protein-coated wells at 371C for 1 or 2 h depending on the cell line. Adhesion was then quantified as described above. Data shown ( ± s.d.) are from one experiment representative of 2 or 3 performed in triplicate. (c) Solubilized proteins (200 mg) from HBMEC were added to 96-well plates precoated with 0.5 mg of CC-PLA2-1 ( ) or CC-PLA2-2 ( ). After incubation for 4 h at 41C and extensive washing, bound integrins were detected by sequential incubations with 10 mg/ml mouse mAbs AMF-7 (anti-av), Gi9 (anti-a2b1) or Sam-1 (anti-a5b1) and with sheep anti-mouse IgG HRP-conjugated antibodies for 1 h at room temperature. Finally, peroxidase substrate was added for 10 min at room temperature, the reaction was stopped by H 2 SO 4 and absorbance was measured at 450 nm.
Integrins, new targets for PLA 2 R Kessentini-Zouari et al 32 This is also the case of sphingosine-1-phosphate, a generally proangiogenic molecule, that inhibits brain-derived endothelial cells migration and in vitro tubulogenesis. 33 The physiological relevance of our in vitro findings on endothelial cells is confirmed by the blockage of in vivo angiogenesis induced by CC-PLA2s.
The inhibitory effect of CC-PLA2s on cell migration and angiogenesis is likely due to the reduced attachment to ECM proteins observed in the presence of the enzyme. As primary receptors for ECM proteins, integrins are required for cell motility. Integrins have also a major role in angiogenesis along with others promoters, such as cadherins, matrix metalloproteinases or growth factors. 1 Initially, the anti-integrin activity among snake venom proteins was considered to be characteristic for disintegrins. 34 However, in the last years increasing evidences show that some CLP can also inhibit integrin-dependent function. 11, 12, 35 Here, we extend this observation to another class of snake venom proteins, the group IIA PLA 2 s.
That CC-PLA2-1 and CC-PLA2-2 impaired angiogenesis by interfering with integrin function is suggested by the fact that both proteins affected adhesion to ECM proteins, but not to the integrin-independent substratum poly-L-lysine. However, all integrins are likely not affected because inhibition was only observed with fibrinogen and fibronectin, but not with other integrins ligands such as type I collagen, vitronectin or laminin 1. In HBMEC, fibrinogen and fibronectin are ligands of a5b1 and av-containing integrins (Supplementary Figure S1) , suggesting that these receptors may be targeted by CC-PLA2s. Indeed, using blocking antibodies and various cell/ECM protein pairs, we observed that both CC-PLA2-1 and CC-PLA2-2 inhibited a5b1 and avcontaining integrins, while having no effect on a1b1, a2b1 and a6b4. Furthermore, CC-PLA2s are able to discriminate between av-containing integrins, as avb3 and avb6 were inhibited, whereas avb5 was not. HBMEC cells express at their cell surface similar high levels of avb3 and avb5, two vitronectin receptors. The fact that avb5 is not inhibited by CC-PLA2s may therefore explains the quasi-absence of effect on HBMEC adhesion to vitronectin. Because each cell type shows its own repertoire of integrins, the functional redundancy of these receptors could also explain the absence of PLA 2 effect reported for some cell types. 31, 32 The inhibitory effect of CC-PLA2s on integrin function could be either direct (eg, physical association with integrins) or indirect (through a third partner). We report in this study that integrins avb3 and a5b1 are still able to interact with CC-PLA2s in a cell-free assay, excluding any effect of PLA2s on integrin subcellular relocalization or activation by intracellular signals. This is in agreement with a recent report showing that secretory group IIA PLA 2 s bind to avb3 and a4b1 integrins and that integrin-PLA 2 interactions may mediate proinflammatory activity. 36 The role of avb3 in the angiogenic process is well documented, 37 with avb3 expression being the most significant alteration in angiogenic endothelial cells relative to quiescent endothelium. 3 In the last decade, several clinical trials evaluating the efficacy of avb3 blockers have led to encouraging results in cancer therapy and diagnosis. However, integrins a5b1 are also involved, as a5-null mouse embryos showed a marked decrease in the complexity of the vasculature when compared with wild-type embryos. 38 The heterodimer a5b1 has also been shown to be expressed in growing vessels but its expression disappears in mature vessels. 39 Consistent with this, our results showed that CC-PLA2s do not affect stable, established blood vessels on CAMs, but strongly reduce the number of new capillaries and vascular branching. Moreover, CC-PLA2s do not affect the viability of stable confluent endothelial cells in vitro.
Thus, the antiangiogenic effect of CC-PLA2s can, at least partly, be due to the blockage of the avb3 and a5b1 integrins function. However, inhibition of angiogenesis can also result from blockage of VEGF or its receptor. Thus, it has been recently reported that inactive PLA 2 homologues, such as KDR-bp isolated from Eastern cottonmouth venom, are common antagonists of KDR, a VEGF receptor. 40 Moreover, interaction with KDR involved clusters of positively charged amino acids present in the C-terminal loop (residues 115-120) and b-wing (Lys 38 and Lys 53 ) regions of KDR-bp. 41 However, as shown in surface electrostatic potential models ( Figure 6 ), both CC-PLA2-1 and CC-PLA2-2 contain negatively charged clusters within their C-terminal loop (residues Glu 115 , Glu 116 and Glu 117 instead of Lys in KDR-pb) and b-wing (Asp 38 and Glu 53 instead of Lys in KDR-pb) regions. Taken altogether, this confirms that CC-PLA2-1 and CC-PLA2-2 likely impair angiogenesis by inhibiting integrins, in particular avb3, rather than the VEGF receptor.
In conclusion, we show for the first time that two PLA 2 s from snake venom are potent integrin inhibitors. These enzymes are able to block endothelial cell adhesion and migration by interfering with a5b1 and av integrins function, resulting in a blockage of angiogenesis. It could thus be interesting to confirm whether this inhibition requires physical interaction with integrins and which are the amino-acid residues involved.
